Drug intelligence / Profile preview

MR-130A-01

Development stage
Phase 3
Lead developer
Viatris
Modality
Transdermal Patches → Device-based Delivery → Drug Delivery Systems
Administration
Transdermal
01

Overview

MR-130A-01 is a progestin-only transdermal contraceptive patch containing norelgestromin (NGMN) as its active ingredient. It is being developed by Viatris (formerly Mylan Pharmaceuticals) as a female contraceptive option. The patch works through a progesterone receptor agonist mechanism, which helps prevent pregnancy by inhibiting ovulation and affecting other physiological functions related to the reproductive system[1][5]. Norelgestromin is already available in combination with ethinyl estradiol (EE) in combined hormonal contraceptive transdermal systems such as Xulane (US) and Evra (EU), but MR-130A-01 is a progestin-only formulation[6][9]. The patch is designed to be applied to the skin (upper outer arm, abdomen, buttock, or back) and changed weekly[9].

Other names
norelgestromin transdermal systemprogestin-only contraceptive patchNGMN patch
02

Targets

PR (Progesterone receptor)

Beyond the preview

Go deeper on MR-130A-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MR-130A-01.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call